2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bone Marrow Failure Syndromes, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4725 Inhibition of the delta opioid receptor (DOR) on myeloid-derived suppressor cells (MDSCs) significantly reduces Cxcl10, Saa3 and Acod1 gene expression, representing a single target to modulate MDSC proliferation, migration and immune suppression.

Krit Ritthipichai, PhD, Edward A. Garcia, B.S.2, Arjun Jayakrishnan3, Maya A. Jerald, DVM4, Ian Frank, BS5, Ruihua A. Chen, PhD6, Taekyoung Kwak, PhD7, Tiffany Razabdouski, B.S.8, Erika Adriana Eksioglu, PhD9, Michael Turner, PhD10, James A. Bianco, MD11
1 TuHURA Biosciences, Tampa, Florida, United States
2 TuHURA Biosciences, Tampa, Florida, United States
3 TuHURA Biosciences, Tampa, Florida, United States
4 TuHURA Biosciences, Tampa, Florida, United States
5 TuHURA Biosciences, Tampa, Florida, United States
6 TuHURA Biosciences, Tampa, Florida, United States
7 TuHURA Biosciences, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 TuHURA Biosciences, Tampa, Florida, United States
11 TuHURA Biosciences, Tampa, Florida, United States

Within the tumor microenvironment (TME), MDSCs impair antitumor immunity through production of reactive oxygen species (ROS), arginase, nitric oxide (NO), and other suppressive mediators that are coordinately regulated at the transcriptional level. Our previous studies demonstrated elevated DOR expression in MDSCs isolated from the 4T1 murine breast tumor model and murine bone marrow-derived MDSCs (mBM-MDSCs) (Cheng et al. (2025) Blood, 146(Suppl 1): 622 and Ritthipichai et al. (2025) Blood, 146(Suppl 1): 1201). Selective pharmacological inhibition of DOR decreased the expression of multiple immunosuppressive genes by qRT-PCR, indicating that DOR contributes to the transcriptional program underlying MDSC suppressive function. However, these findings were limited to a small set of genes. In the present study, we used RNA sequencing (RNA-seq) to define the broader transcriptomic effects of DOR activation and inhibition in MDSCs.

BM-MDSCs were generated from BALB/c murine bone marrow cells cultured with GM-CSF, G-CSF, and recombinant S100A9 for 5 days. Cells received daily treatment with vehicle (DMSO), DOR agonists (ADL5859; 0.1, 1, and 10 μM), or DOR antagonists (HURA-009 or Naltrindole; 0.1, 1, and 10 μM) throughout the differentiation period. Gr-1? cells were enriched by magnetic bead selection and characterized for immunophenotype and DOR expression by flow cytometry. Total RNA extracted from Gr-1? enriched cells was analyzed by bulk RNA-seq (n = 3 per condition), and differential gene expression was analyzed using DESeq2.

Gr-1?-enriched cells consisted of approximately 90% MDSCs, of which 25% were monocytic MDSCs (M-MDSCs) and 75% were polymorphonuclear MDSCs (PMN-MDSCs). More than 95% of MDSCs expressed DOR. MDSC subset distribution and DOR expression were comparable across all conditions, indicating that transcriptomic differences truly reflected altered gene expression rather than shifts in cellular composition. Of approximately 15,000 detected genes, both DOR antagonists (HURA-009 and Naltrindole) consistently downregulated genes associated with migration (Cxcl10; log2FC, -1.48 to -1.83), MDSC suppressive function (Saa3; log2FC, -1.28 to -1.86), and immunometabolism (Acod1; log2FC, -1.08 to -1.46), whereas the DOR agonist (ADL5859) did not significantly alter expression of these genes. Reduced Cxcl10 gene expression may limit recruitment of CXCR3? immunosuppressive populations such as T-bet?CXCR3? regulatory T-cells. Downregulation of serum amyloid A3 (Saa3) gene expression may disrupt autocrine/paracrine feedback via TLR2 and STAT3 signaling, impairing MDSC suppressive function and limiting MDSC accumulation within the TME. RNAi-mediated STAT3 silencing in tumor-associated immune cells increased cytotoxic T-cell infiltration and enhanced anti-PD-L1 efficacy in a checkpoint inhibitor-resistant pancreatic tumor model. Likewise, diminished aconitate decarboxylase 1 gene expression (Acod1) may decrease the production of itaconate, a metabolite that inhibits CD8+ T-cell activation, proliferation, and cytolytic activity, thereby potentially enhancing CD8+ T-cell effector function. Macrophage-specific Acod1 deletion augmented the efficacy of anti-PD-1 therapy in tumor-bearing mice. Together, coordinated gene expression of Saa3 and Acod1 reinforces immune suppression within the TME, promoting immune evasion and resistance to immunotherapy. Collectively, pharmacological inhibition of DOR was associated with coordinated downregulation of genes involved in chemotaxis, immunometabolism, and MDSC suppressive function, supporting the role of DOR signaling in regulating multiple immunosuppressive pathways. Studies examining how DOR inhibition directly modulates TLR2/STAT3 signaling, itaconate-dependent suppression of CD8+ T-cells, and CXCL10-CXCR3-mediated immune cell trafficking are ongoing. Most emerging therapeutic strategies are aimed at targeting MDSCs through metabolic interventions, depletion, and modulation of their recruitment and differentiation. Selective pharmacological inhibition of DOR may represent a novel single-target strategy to reprogram multiple signaling pathways coupled to MDSC-mediated immune cell chemotaxis and immune suppression and help overcome resistance to cancer immunotherapies.
Krit Ritthipichai, PhD: TuHURA Biosciences - Current holder of stock options in a privately-held company; TuHURA Biosciences - Research Funding; TuHURA Biosciences - Current Employment